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Knockdown of Myosin Va Isoforms by RNAi as a Tool
to Block Melanosome Transport in Primary Human
Melanocytes
Mireille Van Gele1, Barbara Geusens1, Anne-Marie Schmitt2, Luc Aguilar3 and Jo Lambert1
The movement of melanosomes, dense melanin-containing organelles, within human melanocytes is actin-
dependent and mediated through the formation of a Rab27a-Slac2-a–myosin Va (MyoVa) protein complex. We
previously showed that only the melanocyte-specific exon F isoforms of MyoVa are involved in melanosome
transport to the dendrite extremities. Here, we investigate siRNA to downregulate the exon F-containing
isoforms of MyoVa in primary human melanocytes. Efficient and specific knockdown of the MyoVa exon F
isofoms were shown at both mRNA and protein levels. Further, a stable shRNA against the MyoVa exon F
isoforms was prepared by using a lentiviral system to improve and confirm the silencing effect in hard-to-
transfect melanocyte cells. Immunofluorescence microscopy shows that knockdown of the exon F isoforms
results in blockade of intramelanocytic melanosome transport due to the inability to form the Rab27a-Slac2-
a–MyoVa tripartite complex. Interestingly, the observed phenotypic effect (that is, perinuclear accumulation of
melanosomes) is the same as that seen in melanocytes from patients with human Griscelli syndrome causing
abnormal pigmentation. We conclude that our siRNA-based strategy provides a previously unreported tool to
block the intracellular melanosome movement in primary human melanocytes and may become an innovative
drug to treat hyperpigmentation.
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INTRODUCTION
Melanocytes in human skin are located in the basal layer of
the epidermis where they produce and store melanin
pigments in specialized lysosome related organelles, the
melanosomes (Marks and Seabra, 2001). After melanosome
maturation at the cell center, they are transported by tubulin-
and actin-dependent motor proteins along the cytoskeleton to
the cell periphery and tips of the melanocyte dendrites
(Lambert et al., 1999). Using their dendritic processes,
melanocytes transfer melanin to the surrounding keratino-
cytes, which is a process that induces skin pigmentation. The
mechanism of melanin transfer from melanocytes to kerati-
nocytes is still unknown, although different hypotheses have
been proposed (Van Den Bossche et al., 2006).
The molecular mechanisms of microtubule to actin-
dependent movement of melanosomes within melanocytes
have been described in great detail. Melanosomes undergo a
long-range movement along microtubules to the cell periph-
ery via the microtubule-based motor proteins kinesin I and
cytoplasmic dynein (Byers et al., 2000; Hara et al., 2000;
Vancoillie et al., 2000a, b). Eventually they are captured in
the peripheral subcortical actin network in the dendrite tips
by the actin-based motor protein myosin Va (MyoVa)
(Lambert et al., 1998a). Rab27a, a small GTPase present on
the membranes of mature melanosomes, recruits its effector,
Melanophilin/Slac2-a, through a direct interaction. In turn,
MyoVa is recruited to the melanosome membrane by
Melanophilin (Wu et al., 2001, 2002a; Fukuda et al., 2002;
Hume et al., 2002; Strom et al., 2002; Westbroek et al.,
2003).
MyoVa is a dimeric molecular motor that moves
processively on actin by converting the energy released by
ATP hydrolysis into mechanical force or movement (Mehta
et al., 1999; Veigel et al., 2002). The molecule consists of two
identical heavy chains that dimerize to produce two actin-
binding head motor domains (amino-terminal) followed by a
neck region containing six repeating amino-acid sequences
(IQ motifs), each binding a light chain (Cheney et al., 1993).
The dimer formation is achieved through an a-helical coiled-
coil structure downstream of the IQ domain. The C-terminal-
located globular tail domain is the cargo-binding site of
ORIGINAL ARTICLE
2474 Journal of Investigative Dermatology (2008), Volume 128 & 2008 The Society for Investigative Dermatology
Received 24 October 2007; revised 14 February 2008; accepted 22 February
2008; published online 10 April 2008
1Department of Dermatology, Ghent University Hospital, Ghent, Belgium;
2Institut de Recherche Pierre Fabre, Centre de Recherche sur la Peau,
Toulouse Cedex, France and 3Pierre Fabre SA, Toulouse, France
Correspondence: Dr Mireille Van Gele, Department of Dermatology, Ghent
University Hospital, P6, De Pintelaan 185, Ghent 9000, Belgium.
E-mail: mireille.vangele@ugent.be
Abbreviations: EGFP, enhanced green fluorescent protein; GS, Griscelli
syndrome; MyoVa, myosin Va; PBS, phosphate-buffered saline; PT, post
transfection; QPCR, quantitative PCR; rHIV-shScr, rHIV-shScrambled
lentiviral vector; RNAi, RNA interference; shRNA, short-hairpin RNA; siRNA,
short interfering RNA; TBS, Tris-buffered saline
MyoVa (Langford, 2002). We described that human MyoVa
undergoes alternative splicing in its medial tail region
through alternate usage of three exons named B, D, and F.
In humans, six endogenously expressed isoforms (ABCDEF,
ACDEF, ABCEF, ABCDE, ABCE, and ACE) were present in
leukocytes and a number of cell types were present in human
skin (Lambert et al., 1998b). Molecular studies revealed that
the transcripts containing exon F are most abundantly
expressed in melanocytes and only those transcripts coloca-
lized with melanosomes (Lambert et al., 1998b; Wu et al.,
2002b; Westbroek et al., 2003). In addition, it has been
shown that presence of both exon F and the globular tail
domain of MyoVa is necessary for actin-dependent melano-
some transport and docking to the plasma membrane; both
domains bind to the middle region of Slac2-a (Fukuda and
Kuroda, 2004; Hume et al., 2006). In melanocytes, over-
expression of recombinant proteins that disrupt formation of
the Rab27a-Slac2-a-MyoVa complex caused perinuclear
melanosome aggregation similar to the phenotype observed
in melanocytes from human Griscelli patients (Pastural et al.,
1997; Lambert et al., 2000; Menasche et al., 2000, 2003a;
Bahadoran et al., 2001, 2003; Westbroek et al., 2004), and in
coat-color-mutant mice (Moore et al., 1988; Mercer et al.,
1991; Huang et al., 1998; Wilson et al., 2000; Matesic et al.,
2001; Hume et al., 2002; Provance et al., 2002; O’Sullivan
et al., 2004) due to dysfunction of the tripartite complex
caused by mutations in either the MyoVa, Rab27a or Slac2-a
gene. Pigmentary dilution of the hair and, to some extent, of
the skin is therefore a common feature of patients with, the
rare, Griscelli syndrome (GS) types 1–3 (Mancini et al., 1998;
Emanuel et al., 2007; Kharkar et al., 2007).
Hyperpigmentation, on the contrary, is a frequently
observed dyschromatosis of the skin (Halder and Nootheti,
2003; Rigopoulos et al., 2007). Most of the time this kind of
pigmentation disappears spontaneously, but in some cases
the course of the disease may be so prolonged, which makes
the condition a chronic problem. The current treatment
methods, such as hydroquinone or kojic acid treatment, are
insufficient and/or can cause side effects, including risk of
post-inflammatory hypo- or hyperpigmentation, ochronosis,
and scarring, producing carcinogenic effects (Briganti et al.,
2003; Halder and Nootheti, 2003; Halder and Richards,
2004; Nikolaou et al., 2006). An increase in melanosome
transport from the melanocytes to the keratinocytes is one of
the underlying biological mechanisms causing hyperpigmen-
tation (Briganti et al., 2003). Modulation of melanosome
capture in the periphery of the melanocytic dendrites by RNA
interference (RNAi), and eventually reducing pigment transfer,
could pave ways to new topical therapeutic developments
for treatment of (hyper)pigmentation.
Here we describe the development of an exon-specific
RNAi method to inhibit the expression of exon F-containing
MyoVa transcripts in cultured primary human epidermal
melanocytes. We show, to our knowledge previously
unreported, that synthetically synthesized short interfering
RNA (siRNA) molecules can successfully be used to knock-
down the exon F isoforms of MyoVa. A long-term silencing of
these exon F isoforms was established in primary melano-
cytes by developing an HIV-based lentiviral expression
system. Immunofluorescence microscopic analysis revealed
that inhibition of MyoVa exon F isoforms resulted in
accumulation of melanosomes around the melanocyte nuclei
and blockade of transport toward the melanocyte tips. We
also demonstrated that knockdown of MyoVa exon F induced
instability of the Rab27a-Slac2-a-MyoVa complex and redis-
tributed Rab27-a and Slac2-a toward the perinuclear region
of the melanocytes.
RESULTS
Efficient and specific downregulation of MyoVa exon
F-containing transcripts by siRNA in human primary melanocytes
We decided to silence the expression of the melanosome-
interacting isoforms of MyoVa by RNAi in cultured primary
human melanocytes. Therefore, three siRNAs targeting the
exon F sequence of MyoVa were designed (see Materials and
Methods). Each siRNA duplex was transfected into melano-
cytes. Real-time quantitative PCR (QPCR) analysis with exon
F-spanning primers revealed downregulation at the mRNA
level by 64% (±3% SEM), 78% (±6% SEM), and 56% (±5%
SEM) for siMyoVa exon F #1, #2, and #3, respectively,
compared with the control (Figure 1a).
To study the effect of silencing over different time periods
(2, 4, 6, and 8 days after transfection), the most efficient
siMyoVa exon F #2 was transfected into primary melano-
cytes. QPCR analysis indicated that siMyoVa exon F #2
downregulated the endogenous MyoVa exon F isoform
mRNA levels by 470%, compared with each control, at a
particular time point. A strong reduction of 82% (±4%) was
still present at day 8 (Figure 1b). Additional experiments
including even longer time points still revealed a reduction of
almost 30% at day 21. Finally, the mRNA expression level of
the exon F isoforms went back to the normal value at 28 days
post transfection (PT) (Figure S1a). Results of silencing were
confirmed by independent use of siMyoVa exon F #1. This
siRNA duplex reduced the MyoVa exon F expression levels to
53% (±3%) on day 8 PT (Figure S1b).
It is known that the mRNA levels of exon F isoforms are
very low in fibroblasts and keratinocytes (Lambert et al.,
1998b; own observations). To verify that the designed siRNAs
specifically downregulated the exon F-containing transcripts,
and not other transcripts, we transfected siMyoVa exon F #2
into HaCaT keratinocyte cells and human fibroblasts. Despite
the low expression levels, we were able to quantify the exon
F-containing transcripts by QPCR and measured a down-
regulation of these isoforms after transfection of siMyoVa
exon F #2 in HaCaT cells and fibroblasts. QPCR analysis
performed with primer sets located outside the exon F target
sequence, and able to amplify all the different MyoVa
isoforms, including those without exon F, revealed no
downregulation in HaCaT cells (Figure 1c) and fibroblasts
(Figure S1c). From these data, we conclude that the isoforms
without exon F, highly expressed in keratinocytes and
fibroblasts, are not targeted and downregulated by siMyoVa
exon F #2. Our designed siRNAs silenced, thus, in a specific
and efficient manner the MyoVa exon F isoforms in primary
human melanocytes.
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To monitor the level of downregulation of exon
F-containing MyoVa isoforms on the protein level, a purified
rabbit polyclonal antibody specifically directed against the
exon F-specific isoforms was made. First, the serum was
tested on three cell lysates made from different human
melanocyte isolates. The rabbit serum labeled the 190-kDa
band, a size typically for the MyoVa protein (Figure S2a).
Second, cell lysates from two different melanocyte donors
and from different human primary fibroblast and keratinocyte
cell cultures were used to assess the specificity of the
antibody in western blot analysis. After a short exposure of
the ECL-stained protein bands to an X-ray film, the anti-serum
labeled the melanocytes but not the fibroblasts and keratino-
cytes. When exposure time was prolonged, only a very faint
staining was observed in the latter cell types in contrast to the
presence of a strong protein band of 190 kDa in the
melanocytes (Figure S2b). From these data, we concluded
that the anti-serum was specific for the exon F-containing
isoforms of the MyoVa protein.
Next, we used the exon F isoform-specific anti-serum to
correlate the observed silencing at the RNA level with protein
downregulation by performing western blot analyses on cell
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Figure 1. Downregulation of MyoVa exon F isoforms by siRNA. (a) Efficiency of siRNA molecules. Melanocytes were transfected with 25 nM of three
different siRNAs targeting exon F. Cells were harvested for RNA 48 hours after transfection. The expression levels of the MyoVa exon F isoforms were
determined by real-time QPCR. The graph shows MyoVa exon F expression levels, normalized to the geometric mean of RPL13a, SDHA, and UBC
housekeeping genes, in siMyoVa exon F-transfected cells relative to that of the cells transfected with the negative control (non-silencing) siRNA (100%).
Black bar, control; white bar, siMyoVa exon F #1; gray bar, siMyoVa exon F #2; and dark gray bar, siMyoVa exon F #3. (b) Time course of MyoVa exon
F mRNA silencing. Normalized expression levels of MyoVa exon F isoforms on mRNA derived from cells at 2, 4, 6, and 8 days after siRNA transfection
were obtained by QPCR and are presented relative to control transfected cells (100%) at every time point. (c) Specific knockdown of MyoVa exon
F isoforms. HaCaT cells were transfected with 25 nM siMyoVa exon F #2 and harvested for RNA 2, 6, and 8 days after transfection. The relative
expression levels are plotted as described in panel (b). QPCR analysis revealed reduction of the MyoVa exon F isoforms (left graph), whereas PCR
amplification with primers located at 50 (MyoVa NH2, middle graph) or 30 (MyoVa globular tail, right graph) of the exon F target sequence showed no
reduction, meaning that the non-exon F isoforms, abundantly present in HaCaT, were not silenced by siMyoVa exon F #2. QPCR data are shown as
means±SEM from three independent experiments. (d) MyoVa exon F protein downregulation. Melanocytes from the same transfection experiments as
described in panel (b) were used for the preparation of whole-cell lysates. Western blots were performed with a rabbit polyclonal anti-MyoVa exon
F antibody. Left: After quantification of band intensities and normalization to tubulin, the MyoVa exon F protein expression in the siMyoVa exon
F #2-transfected cells was plotted relative to that of the control-transfected cells (100%) at each time point. Error bars represent mean±SEM (n¼3).
Right: A Western blot of MyoVa exon F expression, representative for the three experiments, is shown. Tubulin was used as a loading control.
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lysates prepared from the same samples as used in the time-
course experiments described above. Figure 1d shows clearly
that the exon F isoforms are downregulated at the protein
level starting from day 2 after transfection. Parallel to the
results obtained by QPCR at the mRNA level, a protein
downregulation was also seen at day 21 PT, which returned
to normal 28 days PT (data not shown).
Loss of MyoVa exon F isoforms induces perinuclear
melanosome aggregation in human primary melanocytes
The rabbit anti-MyoVa exon F polyclonal antibody was used
to study the endogenous localization of MyoVa exon F in
melanocytes by immunocytochemistry. Laser-scanning mi-
croscopic analysis revealed a strong staining in the tips of the
dendrites and the cell periphery (Figure 2a). This labeling
pattern is similar to that previously observed with antibodies
for MyoVa in this cell type (Lambert et al., 1998a), further
supporting the specificity of our antibody. The exon F
isoform-specific anti-serum was then used in combination
with the melanosomal marker NKI-beteb to analyze the
endogenous expression of MyoVa exon F isoforms and the
distribution of melanosomes in the melanocytes. In control
siRNA-transfected melanocytes, the MyoVa exon F proteins
colocalized, as expected, with the melanosomal marker NKI-
beteb in the periphery and tips of the melanocyte dendrites
(Figure 2a–c). In siMyoVa exon F #2-transfected cells, we
observed strong reduction or loss of endogenous MyoVa exon
F isoforms starting days 2–4 onward. This was associated with
a perinuclear melanosome aggregation in the cells, which
became even more obvious at days 6 (Figure 2e–g) and 8 PT.
Bright-field microscopy also showed clearly the position of
the melanosomes in the cells (Figure 2d versus h). Transfec-
tion of melanocytes with siMyoVa exon F #1 confirmed this
phenotypic effect (data not shown) and illustrated that the
observed effect is not an off-target. These obtained results
emphasize the importance of exon F isoforms in melanosome
transport, and are consistent with those found in melanocytes
overexpressing dominant-negative MyoVa tail constructs
containing exon F, as previously reported by us (Westbroek
et al., 2003).
Lentiviral vector-based shRNAs provide efficient and stable
knockdown of MyoVa exon F isoforms in primary human
melanocytes
To provide long-term silencing model system in hard-to-
transfect melanocytes with high transfection efficiency, we
developed a lentiviral vector system derived from HIV-1 to
express short-hairpin RNA (shRNA) directed against the exon
F-containing isoforms of MyoVa. The sequence of the most
effective siRNA (siMyoVa exon F #2) was used to construct
lentiviral vectors and a control lentiviral vector carrying a
scrambled shRNA (rHIV-shScrambled lentiviral vector (rHIV-
shScr)) was also constructed. In addition, enhanced green
fluorescent protein (EGFP) was incorporated as a reporter
gene to follow transduction efficiency. The transduced
melanocytes were examined for EGFP expression with a
fluorescence microscope every 2 days post-transduction and
were split when necessary. Infected cells were found to
maintain expression of EGFP at early post-infection days
through at least 4 weeks (duration of analysis) following
infection (data not shown). Furthermore, time-course analysis
of rHIV-shMyoVa exon F-transduced melanocytes revealed
decreased mRNA level of MyoVa exon F transcripts of 75%
even 3–4 weeks after transduction as compared with MOCK-
transduced cells (Figure 3a, top); a similar reduction was seen
siControl siMyoVa exon F #2
a e
b f
c g
d h
Figure 2. siRNA-mediated depletion of MyoVa exon F induces perinuclear
melanosome aggregation. Melanocytes transfected with siControl (a–d) and
siMyoVa exon F #2 (e–g) were fixed 6 days after transfection, co-
immunostained with a rabbit polyclonal anti-MyoVa exon F antibody and a
mouse monoclonal anti-NKI-beteb antibody, and then visualized with an
Alexa Fluor 594 (red) and an Alexa Fluor 488 (green) secondary antibody,
respectively. MyoVa exon F is present in the periphery and the tips of the
dendrites (a) and NKI-beteb shows normal melanosomal distribution (b) in
control-transfected cells. Colocalization of the two markers is shown in panel
(c). Reduced or no staining of MyoVa exon F is shown in panel (e) and the
asterisks indicate cells with observed perinuclear aggregation of
melanosomes (f). An overlay of the image in panels (e) and (f) is shown in
panel (g). Nuclei were counterstained in blue with 40,6-diamidino-
2-phenylindole. The bright-field images depict siControl melanocytes with
pigment accumulation in dendrites and the dendritic tips (d, arrows) and
siMyoVa exon F-transfected cells with perinuclear clustering of melanosomes
(h, asterisks). Bars¼ 50 mm.
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at the protein level (Figure 3a, bottom). In contrast, infection
of melanocytes with a control rHIV-shScr revealed no
reduction of MyoVa exon F at the mRNA and protein level.
By performing additional western blot analysis with the same
cell lysates, we noticed that silencing of MyoVa exon F
resulted in a decrease of Rab27a, whereas the protein level of
Slac2-a remained unchanged (Figure 3a, bottom). The above
experiment was repeated with melanocytes isolated from
another donor and revealed the same results (Figure 3b).
Blockade of melanosome transport and inhibition of Rab27a-
Slac2-a–MyoVa tripartite complex formation after transduction
of lentiviral shRNA vectors in primary human melanocytes
To analyze the phenotypic effect of lentiviral RNAi in primary
human melanocytes, cells were grown on coverslips and
transduced with rHIV-shMyoVa exon F or rHIV-shScr. Cells
were fixed at different time points (day 14, day 21, and day
28) and used for immunocytochemistry. The cells were first
immunostained with the anti-MyoVa exon F polyclonal
antibody. In EGFP-positive cells expressing shRNAs against
MyoVa exon F, endogenous MyoVa exon F protein expres-
sion was strongly reduced or completely absent (Figure 4a–c),
whereas in melanocytes transduced with rHIV-shScr, im-
munostaining signals of endogenous MyoVa exon F proteins
were observed in the tips of the dendrites and cell periphery
(Figure 4e). To observe the effect of the expressed MyoVa
exon F, shRNAs on melanosome distribution transduced
melanocytes were stained with the NKI-beteb antibody.
EGFP-positive MyoVa exon F-deficient cells showed peri-
nuclear aggregation of melanosomes (Figure 4g–i). A normal
distribution was observed in melanocytes transduced with
rHIV-shScr (Figure 4k). These results are in agreement with
those observed in melanocytes transiently transfected with
siRNA, as described earlier in this study. Furthermore,
specific labeling for the actin cytoskeleton showed no
disruption of actin filaments in MyoVa exon F-deficient cells
as compared with controls, indicating that the change in
melanosome distribution is caused by specific loss of MyoVa
exon F protein expression and not due to defects in the actin
network (Figure 4m–o versus q). The bright-field images also
illustrate the difference in melanosome distribution between
rHIV-shMyoVa exon F and rHIV-shScr-transduced melano-
cytes (Figure 4d, j, p versus f, l, r).
To examine the effect of depletion of MyoVa exon F
proteins on the localization of the other members of the
molecular tripartite complex, lentivirus-transduced cells were
stained with a Rab27a or Melanophilin/Slac2-a antibody.
Fluorescence images of rHIV-shMyoVa exon F-treated cells
showed that the Rab27a or Slac2-a immunoreactivity was not
lost by silencing MyoVa exon F, but their distribution in the
melanocytes changed, however, from the peripheral area and
tips of dendrites to perinuclear localization (Figure 4s and w,
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Figure 3. Stable knockdown of MyoVa exon F isoforms by lentiviral RNAi in melanocytes isolated from two different donors. (a) Melanocytes were
MOCK-treated and infected with viruses expressing scrambled shRNA or shRNA against exon F of MyoVa. Cells were harvested at the indicated time
points and used for the preparation of RNA and whole-cell lysates. The expression levels of the MyoVa exon F isoforms were determined by
real-time QPCR. The graph (top) shows MyoVa exon F normalized expression levels in shScrambled- and shMyoVa exon F-transduced cells relative to
that of the MOCK-treated cells (100%) at each time point indicated. The data shown are from one transduction experiment; error bars indicate
mean±SD on PCR duplicates. Bottom: Whole-cell lysates were analyzed by western blotting using antibodies to each individual protein member of
the Rab27a-Slac2-a–MyoVa tripartite complex. (b) Melanocytes were MOCK treated and infected only with viruses expressing shRNAs against exon
F of MyoVa. Processing of samples and data analysis was performed as described in panel (a). The graph (top) shows data of a second, but different,
transduction experiment; error bars indicate mean±SD on PCR duplicates. A 75% (±4%) reduction of MyoVa exon F mRNA expression level is
still observed at 28 days after infection. Bottom: Western blotting results of endogenous MyoVa exon F, Slac2-a, and Rab27a proteins.
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respectively), compared with control-transduced melano-
cytes (Figure 4u and y, respectively). From these data, we
concluded that the tripartite complex did not form when exon
F-containing MyoVa isoforms were knocked down, which in
turn induced accumulation of melanosomes around the
nuclei of melanocytes (see also Figure 4t, x versus v, z).
DISCUSSION
In this study, we developed an exon-specific RNAi approach
to downregulate the melanocyte-specific exon F isoforms of
the molecular motor MyoVa. First, we examined the use of
synthetic, 21-mer siRNA duplex molecules in primary human
melanocytes for transient gene silencing. We were successful
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Figure 4. Knockdown of MyoVa exon F by lentiviral RNAi results in blockade of melanosome transport and disruption of the Rab27a-Slac2-a–MyoVa tripartite
complex. Melanocytes were transduced with shRNA against MyoVa exon F to allow depletion of MyoVa exon F isoforms or were transduced with scrambled
shRNA as control. Cells were fixed at the desired time points. Cells contained enhanced GFP as an expression marker and were stained with specific antibodies
against the indicated proteins or with phalloidin. MyoVa exon F is knocked down (a–c) and staining with a melanosomal marker (NKI-beteb) reveals
accumulation of melanosomes around the cell nuclei (g–i) in shMyoVa exon F-transduced melanocytes (EGFP-shMyoVa exF), whereas expression of MyoVa
exon F and normal melanosome distribution is observed in controls (e and k, respectively). The actin cytoskeleton is intact (m–o versus q). The bright-field images
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transduction). As a result of MyoVa exon F protein loss, Rab27a and Slac2-a were relocalized to the perinuclear region (indicated by asterisks in s and w,
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2-phenylindole, except in panels (w, y). Panels (t, v, x and z) show bright-field images showing the pigment granules. Bars¼ 50 mm.
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at finding accessible siRNA target sites on the short (75 bp)
exon F sequence and showed that our designed siRNAs could
specifically and efficiently inhibit the expression of MyoVa
exon F isoforms at the mRNA, protein, and functional levels.
Extended time-course experiments revealed that the RNAi
activity lasted for a relatively long time period (421 days) in
our siRNA-transfected primary melanocytes, but the effi-
ciency of silencing was decreasing over time, confirming the
transient nature of siRNAs. Nevertheless such an extended
RNAi effect has never been reported previously for human
melanocytes partially because (1) few studies are published
to date where primary human melanocytes are transfected
with siRNAs and (2) a common practice of researchers is to
look at time points within 2 and 4 days. In mammalian cells,
siRNA duplexes become progressively diluted as the cells
divide, due to lack of RNA-dependent RNA polymerases
(Holen et al., 2002; Kisielow et al., 2002; Leung and
Whittaker, 2005). A recent study by Bartlett and Davis
(2006), examining the kinetics of siRNA-mediated silencing
in vitro, showed that the time of the gene silencing varies
mainly with the proliferative status of the cells. Primary
human melanocytes are slowly dividing cells (mean doubling
time of approximately 7–10 days), and therefore the dilution
effect is less pronounced in these cell types, and this probably
contributes to the extended silencing effect observed in this
study. In addition, a phenotypic effect (perinuclear aggrega-
tion of melanosomes) became evident after microscopic
analysis of MyoVa exon F-silenced cells.
In a second part of this study, we successfully developed a
lentiviral vector system expressing shRNAs against the melano-
some-binding sequence exon F of MyoVa. Interestingly,
infection of primary melanocytes with viruses expressing
MyoVa exon F shRNAs led to inhibition of the formation of
the Rab27a-Slac2-a–MyoVa tripartite complex as observed by
redistribution of melanosomes from the peripheral to the
perinuclear region. The fact that we obtained, here, a biological
effect, which remains stable for several weeks in vitro, is a major
benefit for long-term studies in more complex model systems.
Knockdown of endogenous MyoVa exon F followed by
western blotting with antibodies specific for Rab27a and
Slac2-a revealed that the overall stability of the Rab27a-
Slac2-a–MyoVa tripartite complex was affected. Indeed, the
protein expression level of Rab27a was reduced, whereas
that of Slac2-a remained constant after MyoVa exon F
knockdown. Immunocytochemical analysis of MyoVa exon
F-deficient cells clearly showed that the remaining Rab27a
protein and Slac2-a were maintained on the melanosomal
membranes. Our findings are in partial agreement with a
recent report by Hume et al. (2007) who used siRNA
oligonucleotides against each member of the tripartite
complex in mouse melanocyte cell lines. In the latter study,
the expression level of Slac2-a but not Rab27a was reduced
after depletion of MyoVa. Our study is to our knowledge the
first report examining MyoVa exon F downregulation in
human melanocytes. The difference between our results and
those of Hume et al. (2007) could be species-related.
Anyway, previous studies in human melanocytes showed
that Rab27a is particularly involved in the assembly of the
tripartite complex on melanosomes (Wu et al., 2001, 2002a;
Fukuda et al., 2002; Hume et al., 2002; Strom et al., 2002;
Westbroek et al., 2003). Its function in human melanocytes is
thereby confined to regulation of peripheral melanosome
distribution. Therefore, we assume that after loss of MyoVa
exon F and inhibition of intracellular melanosome transport,
a high expression level of Rab27a is no longer needed or that
the protein becomes degraded (after membrane dissociation).
The remaining stability of Slac2-a could possibly point at the
fact that Slac2-a binds also other proteins not necessary
involved in melanosome transport. We hypothesize that
endogenous Slac2-a in human melanocytes might interact
with, for example, the microtubule plus-end-tracking protein
EB1, as has been shown in mouse melanocytes (Wu et al.,
2005; Hume et al., 2006, 2007), or with other, not yet
identified, proteins. Further studies on human melanocytes
should reveal whether the function of Slac2-a consists of
more than just being involved in the Rab27a-Slac2-a–MyoVa
tripartite complex and intracellular melanosome transport.
As the transport of melanosomes to the tips of the
dendrites was inhibited in our shMyoVa exon F-transduced
melanocytes, we hypothesize that these melanocytes stopped
making new melanosomes. A continuation of this process
would possibly result in cytotoxicity and finally death of the
melanocytes. This blockade of melanosome synthesis pro-
bably also occurs in some pigmentary disorders such as the
rare, autosomal recessive Griscelli disorder (Pastural et al.,
1997; Lambert et al., 2000; Menasche et al., 2000, 2003a;
Bahadoran et al., 2001, 2003; Westbroek et al., 2004), where
melanosome transport is abnormal. The melanocytes of
Griscelli patients are intact, but clustering of melanosomes
around the nuclei has also been observed due to dysfunction
of the Rab27a-Slac2-a–MyoVa molecular tripartite complex
caused by mutations in either the MyoVa (GS type I), Rab27a
(GS type II), or Slac2-a (GS type III) gene. Whereas the
melanocytes contain a large volume of melanin, the
surrounding keratinocytes are devoid of melanin due to
transfer blockade of these granules (Van Den Bossche et al.,
2006). This explains why patients presenting with GS are
characterized by pigmentary defects resulting in silvery-gray
color of the hair and pigmentary dilution of the skin.
Neurological and immunological dysfunctions are addition-
ally observed in GS type I and type II, respectively.
Interestingly, GS type III shows a phenotype restricted to
hypopigmentation due to mutations in Melanophilin/Slac2-a
(Menasche et al., 2003b). In the same paper, the authors
described a patient bearing a MyoVa exon F deletion with the
same dilution phenotype as in GS type III (Menasche et al.,
2003b). The occurrence of this single effect is likely
contributed to by the fact that MyoVa exon F isoforms are
predominantly expressed in melanocytes and not neurons, for
example. On the basis of this consideration and our data, we
propose that abrogation of these exon F-containing isoforms
by siRNA-mediated gene silencing could influence (hyper)-
pigmentation. Even the lower protein amount of Rab27a will
not result in adverse side effects in melanocytes. Several
studies demonstrated already that Rab27a colocalized with
melanosomes in either human and mouse melanocytes,
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meaning that Rab27a is specifically involved in the melano-
some transport pathway (Bahadoran et al., 2001; Hume et al.,
2001). Moreover, in melanocytes of GS type II patients,
melanosomes are clumped in perinuclear regions, whereas
cells themselves and their dendrites appear normal (Bahador-
an et al., 2001, 2003). Whether downregulation of MyoVa
exon F (and Rab27a) in other cell types of the skin eventually
causes cytotoxicity or other undesirable non-pigmentation-
related defects will be a subject for in vivo studies.
In summary, we used RNAi to downregulate the expression
of the melanosome-interacting exon F isoforms of the molecular
motor protein MyoVa in primary human melanocytes cultured
in vitro. Specific knockdown of the MyoVa exon F isoforms
resulted in transport inhibition of melanosomes to the peripheral
subcortical actin network in the dendrite tips; perinuclear
aggregation of the melanosomes, a phenomenon also seen in
the melanocytes of GS patients, was observed. If confirmed
in vivo, use of exon F-specific RNAi in melanocytes could open
ways for a new topical application to treat some hyperpigmen-
tary disorders by blocking intramelanocytic melanosome
transport and eventually reducing pigment transfer from
melanosomes to the surrounding keratinocytes.
MATERIALS AND METHODS
Cell culture
Primary epidermal melanocytes were established as described
previously (Naeyaert et al., 1991). Briefly, foreskins from neonatals
were incubated overnight at 4 1C in 10% Dipase II (Roche
Diagnostics GmbH, Mannheim, Germany) to separate the epidermal
layer (with melanocytes anchored to the basal membrane) from the
underlying dermis. Melanocytes were cultured in Ham’s F10
medium (Invitrogen Ltd, Paisley, UK) supplemented with 2.5% fetal
calf serum, 1% Ultroser G, 5 ngml1 basic fibroblast growth factor,
10 ngml1 endothelin-1, 0.33 nM cholera toxin, 0.033nM isobutyl-
methyl-xanthine, 5.3 nM 12-O-tetradecanoyl phorbol-13-acetate,
and antibiotics/antimycotics. The human keratinocyte cell line
HaCaT was grown in DMEM (Invitrogen Ltd) supplemented with
2mM L-glutamine, 10% fetal calf serum, and 1% antibiotics/
antimycotics. Human fibroblasts were cultured in Optimem medium
(Invitrogen Ltd) supplemented with 2% Ultroser G, 2mM
L-glutamine, 5% fetal calf serum, and 1% antibiotics/antimycotics.
All cells were kept in an incubator at 37 1C, 99% humidity, under
10% CO2. All experimental procedures were approved by the
Institutional Review Board (Ghent University, Faculty of Medicine)
and adhered to the Declaration of Helsinki Principles.
Design and transfection of siRNA
The complete sequence of exon F was derived from the partial
coding sequence of human MyoVa mRNA (accession number
AF090424). Three siRNA sequences targeting exon F were designed
on request by Eurogentec (Seraing, Belgium). The freely available
siRNA design and order form can be found at http://www.eurogen-
tec.com/product/research-custom-sirna.html. The following
sequences were used to target exon F: siMyoVa exon F #1,
50-UGACCCUAAGAAGUAUCAA-30 (nucleotides 642–660); siMyoVa
exon F #2, 50-GUAUCAAUCAUAUCGGAUU-30 (nucleotides
654–672), and siMyoVa exon F #3, 50-UCAUAUCGGAUUUCC
CUUU-30 (nucleotides 661–679). A BLAST search was performed to
check for specificity. No homology was found to any other known
gene. All siRNAs were chemically synthesized by Eurogentec.
Annealing was performed according to the manufacturer’s protocol.
This resulted in a 20 mM final concentration of the siRNA duplexes.
For QPCR and western blot analysis, human primary melano-
cytes were plated into 60-mm dishes at a density of 8 105 cells per
dish 24 hours before transfection. Each dish contained 4ml of serum-
containing Ham’s F10 medium (see above). On the day of
transfection, the medium was replaced with 2.4ml of fresh medium.
The siRNA was diluted in 100ml of culture medium without serum (to
get a final siRNA concentration of 25nM after adding complexes to the
cells) and 18ml of HiPerFect Transfection Reagent (Qiagen, Hilden,
Germany) was added. This solution was mixed by vortexing and
incubated for 10minutes at room temperature to allow formation of
transfection complexes. These complexes were added in a drop-wise
manner onto the cells. The medium was replaced 24hours later and
gene silencing was monitored at the desired time points by harvesting
one-third of the cells for RNA isolation and the other two-thirds was
used to prepare whole-cell lysates (see further). All transfections were
performed in triplicate. A BLOCK-iT Negative Control oligo from
Invitrogen was used as control. This sequence shows no homology to
any known gene. The same transfection procedure was followed for
HaCaT cells or human fibroblasts, except that each cell type was
grown in their respective culture medium. For immunocytochemistry,
primary melanocytes were cultured and transfected in the same way
as above, but seeded first on sterile coverslips at a density of 1 105
cells per 60-mm dish. Each experiment was repeated at least once on
melanocytes isolated from a different donor.
Lentiviral vector construction, virus production, and infection
Plasmids containing MyoVa exon F #2 shRNA or scrambled shRNA
(the scrambled 50-AUUAUCUAGGAGAUAUCAC-30 sequence for
shRNA design was based on the nucleotide composition of siMyoVa
exon F #2) and EGFP as marker were constructed by Vectalys
(Labe`ge Cedex, France) in order to obtain rHIV-shMyoVa exon F and
rHIV-shScr lentiviral vectors. Pairs of complementary DNA oligo-
nucleotides containing MyoVa exon F #2 or the scrambled
sequences were synthesized by MWG Biotech (Roissy, France) and
hybridized to generate dsDNA. Each dsDNA was cloned into a
lentiviral plasmid containing a human H1-RNA polymerase III
promoter by cohesive BglII/SalI ligation. Thereafter, 200-ml cultures
of plasmids pHIV-H1shMyoVa exon F and pHIV-H1shScrambled
were obtained. Subsequently, recombinant lentiviral vectors were
produced by tri-transfection into human 293T cells by using standard
calcium phosphate procedures. Twenty-four hours after transfection,
cells were washed with the medium. Viral supernatants were
collected 24 hours later and filtered through a 0.45-mm filter. The
titers were estimated by FACS and QPCR after 72 hours of infection
of HCT116 cells transduced by a serial dilution of viral supernatants.
The titer of each batch of lentiviral vectors (rHIV-shMyoVa exon F
and rHIV-shScr) was 106 transducing units per ml.
To find a minimum effective multiplicity of infection, several
multiplicities of infection (2.5, 5, and 10) of the viral preparations
were tested by infecting 100,000 melanocytes (in duplicate) grown
in 24-well plates. Briefly, after growing cells for 24 hours, the
medium was replaced by different volumes of the retroviral
supernatant and fresh medium supplemented with 4 mgml1
polybrene (Sigma-Aldrich, Bornem, Belgium). Two rounds of
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infection, 4 hours each at days 1 and 2, were performed by replacing
the supernatant with fresh medium. The percentage of transduced
cells was estimated 48hours after the last cycle by flow cytometry
using the EGFP fluorescence as a reference. A multiplicity of infection
of 10 resulted in the highest transduction efficiency (490%).
Subsequently, all transductions were performed at a multiplicity of
infection of 10. For QPCR and western blotting, 300,000 melano-
cytes were grown in each well of a six-well plate. For immunocy-
tochemical analysis, 100,000 melanocytes were grown on glass
coverslips in six-well plates. The cells were transduced with MOCK
(only polybrene), rHIV-shMyoVa exon F, and rHIV-shScr. The
transduced melanocytes were trypsinized and further processed for
RNA and whole-cell lysates, or fixed in 3% paraformaldehyde
solution at the desired time points as described further below.
Flow cytometry
EGFP-positive cells were analyzed with a FACSs Calibur flow
cytometer (Becton Dickinson Immunocytometry Sytems, Mountain
View, CA) using CellQuest software.
RNA isolation and real-time quantitative reverse transcription
PCR
Total RNA was extracted from melanocytes using the RNeasy Mini
kit (Qiagen, Venlo, The Netherlands) according to the manufac-
turer’s recommendations. All RNA was quantified using an ND-1000
spectrophotometer (Isogen, Life Science, St-Pieter leeuw, Belgium).
Total RNA (2mg) was treated with the RQ1 RNase-free DNase from
Promega (Leiden, The Netherlands). In addition, the treated RNA
samples were desalted prior to cDNA synthesis using Microcon-100
spin columns (Millipore, Brussels, Belgium). First-strand cDNA was
synthesized using the iScript cDNA Synthesis kit according to the
manufacturer’s instructions (Bio-Rad, Eke, Belgium) and subse-
quently diluted with nuclease-free water (Sigma-Aldrich) to
12.5 ng ml1 cDNA. To quantify the gene expression level of MyoVa
exon F transcripts, primer sequences were designed using Primer
Express software (Applied Biosystems, Foster City, CA) and were
placed on exons E and F (accession number AF090424). In this way
all MyoVa isoforms containing exon F were amplified. Additional
primers were also designed at the 50 end (named NH2) and at the
30 end (named globular tail from globular tail) of the MyoVa gene
(based on accession number NM_000259). A BLAST search was
used to assure that these primers were specific for MyoVa only. The
primer sequences are available upon request. Relative gene
expression levels were determined using a SYBR Green I reverse
transcription-PCR assay as described by Vandesompele et al. (2002a)
and the comparative Ct method was used for quantification. PCR
reagents were obtained from Eurogentec as SYBR Green I Master
Mixes, and used according to the manufacturer’s instructions. PCR
reactions were run on an ABI prism 7000 Sequence Detection
System (Applied Biosystems). To correct for differences in RNA
quantities and cDNA synthesis efficiency, relative gene expression
level were normalized using the geometric mean of three house-
keeping genes (RPL13A, UBC, and SDHA) according to Vandesom-
pele et al. (2002b). In each experiment, the mean normalized
expression level (%) of MyoVa exon F in each transfected sample
was compared with that of its corresponding non-silencing siRNA
(control) at a particular time point. The same experimental
procedure was followed for HaCaT and human fibroblast cells,
except for the use of the housekeeping genes (glyceraldehyde-
3-phosphate dehydrogenase, HMBS, and b-actin were used for
HaCaT cells, and SDHA, glyceraldehyde-3-phosphate dehydrogen-
ase, and YWHAZ for fibroblasts).
Production of rabbit anti-MyoVa exon F polyclonal antibody
and western blotting
A rabbit anti-serum was prepared against a unique peptide sequence
within exon F of MyoVa (amino acids 211–223 of human exon F
sequence, residues YADDPKKYQSYR). The peptide (30mg) and the
polyclonal serum directed against it were prepared by Eurogentec.
The immunization and bleeding protocol with reference AS-PAFF-
RABBIT was followed. Detailed information can be found at http://
www.eurogentec.com/product/research-anti-peptide-87-day-polyclo-
nal-packages.html. The preimmune serum and several test bleedings
were checked for their activity against MyoVa exon F proteins in our
laboratory. Finally 50ml of the final bleed serum was purified, ELISA-
tested, and run on an SDS–PAGE gel by Eurogentec for quality control.
For western blotting, cultured melanocyte cells (or HaCaT or
human fibroblast cells) were lysed by resuspension in a buffer
(10mM Tris, pH 7.4, 150mM NaCl, 1mM EDTA, 0.4% NP-40). A
protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO) was
added to reduce proteolysis. Total cellular extracts (10 mg) were
solubilized and denatured by boiling in 1 /4 Laemmli sample
buffer containing 5% b-mercaptoethanol and 0.25% bromophenol
blue. Proteins were separated by SDS–PAGE (6% gels) and
transferred onto nitrocellulose membranes (Amersham Biosciences
UK Ltd, Buckinghamshire, UK). Membranes were blocked for 1 hour
at room temperature in 5% non-fat dry milk dissolved in Tris-
buffered saline (TBS) with 0.1% Tween-20, followed by 2 hours of
incubation with the primary antibody. The primary antibodies
included purified rabbit anti-MyoVa exon F serum diluted
1:15,000 in TBS with 0.1% Tween-20, a mouse mAb against
Rab27a (1:500; BD Transduction Laboratories, Lexington, KY), a
rabbit anti-Melanophilin polyclonal antibody (1:500; ProteinTech
Group, Chicago, IL), and a mouse mAb anti-a-tubulin clone B-5-1-2
(1:8,000; Sigma-Aldrich). The latter was used to control loading and to
perform normalization. After several washing steps with TBS with 0.1%
Tween-20, the blots were incubated with the appropriate horseradish
peroxidase-conjugated secondary antibody (1:3,000; Amersham Bios-
ciences UK Ltd) for 1hour at room temperature. After final washing
steps with TBS with 0.1% Tween-20, protein bands were visualized
with the enhanced chemiluminescence kit (Amersham Biosciences UK
Ltd) according to the manufacturer’s protocol, and the membrane was
exposed to X-ray films. When needed, scanned protein bands were
quantified with Quantity One Software (Bio-Rad).
Immunocytochemistry
Transfected melanocytes were grown on glass coverslips, washed in
1 phosphate-buffered saline (PBS), and fixed in 3% paraformalde-
hyde solution in PBS for 20minutes. Excess fixative was removed by
washing in PBSE (Eisen formulation) and cells were submerged for
10minutes in 50mM NH4Cl in PBS
E, followed by three washes in
TBS. For permeabilization, cells were treated for 5minutes with
0.2% Triton X-100 in PBSE. A blocking step was performed by
incubating the cells in solution 1 (PBS, 0.5% BSA) for 30minutes.
Primary antibodies were diluted in solution 1 before use. To co-
immunostain MyoVa exon F and the melanosome marker NKI-beteb,
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cells were incubated with a polyclonal anti-MyoVa exon F antibody
(dilution, 1:500; made by Eurogentec (see above)) and a mouse
monoclonal NKI-beteb antibody directed against the (pre)melano-
somal silver protein (dilution, 1:40, melanoma-associated antigen,
100 kDa; Monosan, Uden, the Netherlands) for 2 hours at room
temperature. After three washes in TBS, the coverslips were
incubated for 1 hour with an Alexa 594-conjugated mouse anti-
rabbit antibody (1:1,000) and an Alexa 488-conjugated rabbit anti-
mouse (1:1,000) secondary antibody (Invitrogen SA, Merelbeke,
Belgium). The same antibodies were used for single staining on
lentivirus (EGFP)-transduced melanocytes. For staining of Rab27a
and Melanophilin/Slac2-a, the primary antibodies were the same as
used as for western blotting, but were in other dilutions, 1:100 and
1:20, respectively. Detection was with appropriate Alexa 594-
conjugated secondary antibodies. The stained cells were washed
again three times in TBS, the first wash solution contained 40,6-
diamidino-2-phenylindole for detection of cell nuclei. Cells were
mounted on glass slides with Glycergel (DakoCytomation, Carpin-
teria, CA) and optical sections (1mm) were obtained with a Leica TCS
SP5 AOBS Laser Scanning Confocal Microscope (Leica Microsystems
GmbH, Wetzlar, Germany) fitted with a  63 oil-immersion
objective.
For actin labeling, cells were incubated with the fluorescent
F-actin probe TRITC phalloidin (Sigma-Aldrich) after the blocking
step as described above. Melanosome distribution was analyzed
in the following manner: cells in which more than half of the
melanosomes were located around the nucleus were classified as
those with a perinuclear melanosome aggregation effect.
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